Apurvasena Parikh

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

John H. Strickler, Colin D. Weekes, John Nemunaitis et al. · Journal of Clinical Oncology · 2018 · 135 citations · Full text

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman et al. · Journal of Clinical Oncology · 2022 · 97 citations · Full text

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist et al. · Clinical Cancer Research · 2021 · 74 citations · Full text

Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection

Prajakta Badri, Apurvasena Parikh, Eoin Coakley et al. · Therapeutic Drug Monitoring · 2016 · 30 citations

Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma

Apurvasena Parikh, Sathej Gopalakrishnan, Kevin J. Freise et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2017 · 26 citations